News

Dr. Kathleen Bethin, clinical professor, and Dr. Lucy Mastrandrea, associate professor and division chief of endocrinology/diabetes both at the Jacobs School of Medicine & Biomedical Sciences at the University at Buffalo, spoke with Vic Baldry of Cecelia Health to discuss the challenges telehealth has created when caring for families with children who have type 1 diabetes.

Biomarker status can help clinicians and patients make informed, personalized treatment decisions, whether the choice is an FDA-approved targeted therapy or a clinical trial.

Corticosteroids are a mainstay but the introduction of biologics has transformed the management of this severe form of asthma.

The use of accurate biomarkers for detecting autism spectrum disorder could result in saving billions of dollars in healthcare costs, according to a paper recently published in the journal Autism Research.

But many devices don’t communicate with a patient’s electronic health record.

In this week's episode of "Tuning In to the C-Suite" podcast, Senior Editor Peter Wehrwein spoke with Debra Cooper, RN, MSN, MBA/HCM, a senior risk specialist at Coverys, a medical malpractice insurance company headquartered in Boston. Wehrwein and Cooper discussed the role the company has played in advising providers during the COVID-19 pandemic, risk mitigation, and the role they can now play in overcoming vaccine hesitancy.

Opdivo is the first FDA-approved immunotherapy for the first-line treatment of gastric cancer.

Access to care and other health disparities result in the low use of novel therapies for Black, female and lower income type 2 diabetes patients. If these barriers aren't addressed, disparities among kidney and cardiovascular patients may worsen in the U.S.

The FDA approved proton beam radiation in 1988. But whether it is an improvement over conventional photon radiation as a treatment for many cancers remains an open question.

The Blue Cross Blue Shield Association's new strategy sets their goal to reduce racial disparities in maternal health by 50% in five years.

The four historically Black medical schools are part of the answer as U.S. healthcare reckons with racism and inequity. They are expanding and receiving record levels of donations.

A Medicare Advantage group and other organizations are endorsing legislation that would allow data collected during audio-only visits to be used to set risk adjustment payment levels to MA plans.

The combination monoclonal antibody treatment of bamlanivimab and etesevimab still OK.

Automated texts may also lessen the workload on nurses.

Brooks, senior medical director of Independence Blue Cross in Philadelphia, was a key member of the team that created a health awareness campaign launched earlier this month in cooperation with local radio station WURD and other partners including the Colorectal Cancer Alliance, the Independence Blue Cross Foundation, Penn Medicine, Labcorp, and the Health Care Improvement Foundation. The campaign, called “Go To Know,” sets out to increase colon cancer screenings among African Americans by providing free Fecal immunochemical, or FIT, tests.

A new survey revealed a majority of health organizations have lack of awareness and are unprepared to comply with the ONC's final rule act of information blocking and improving interoperability provisions. Matthew A. Michela, President and CEO, Life Image, shares how to get on board.

In this third part of a three-part series, Steven D. Pearson, M.D., M.Sc., founder and president of ICER talks the drug Inclisiran and its relation to PCSK9 inhibitors.

A recent survey by Scripta Insights shows 96% of consumer are willing to make a prescription change as far as switching their medications, forms and where they fill in order to save money.

The number of participants in the Medicare Shared Savings Program has tapered off, and the Direct Contracting Model may put accountable care organizations at a disadvantage. The National Association of ACOs wants the Biden CMS to make some changes.

In this second part of a three-part series, Steven D. Pearson, M.D., M.Sc., founder and president of ICER addresses if pricing of PCSK9 inhibitors put ICER on the map.

Burnout among nurses has been a major pain point for hospitals and health systems long before COVID. Nurses work long hours and face a unique combination of physical and emotional challenges, and a seemingly simple mistake can be fatal. As a result, burnout rates among nurses range from 15% to 45%, leading 1 in 3 nurses to leave the bedside within their first two years.

The triptans, long the workhorses of migraine treatment, have been joined by monoclonal antibodies and small-molecule drugs that block calcitonin gene-related peptide. What’s lacking is a precision approach to treatment based on biomarkers.

In this week’s episode of Tuning In to the C-Suite podcast Briana Contreras, associate editor of Managed Healthcare Executive, spoke with David Lareau, CEO of Medicomp Systems about four areas that must be addressed to improve the usability of health IT, address interoperability issues, and minimize clinician burden.

The new approval expands the drug's indication to include treatment in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer.

Whether the cup of value-based care is half empty or half full may depend on your point of view. But the grail certainly isn’t full. Some of the leading lights at the Leonard Davis Institute (LDI) of Health Economics at the University of Pennsylvania have released recommendations to hasten the volume-to-value healthcare transformation.

Two common antidepressant and antifungal drugs were very effective at inhibiting SARS-CoV-2, the virus that causes COVID-19, according to a new study.

A couple of years ago, there was a lot of chatter about the Amazonifcation of healthcare. Well, that hasn’t happened. But the company is breaking into a sector of the economy that accounts for almost 18% of the American gross domestic product. Perhaps healthcare’s journey of Amazonifcation has started but is going step by step.

The Biden administration put a hold on the new and pending rule changes that the outgoing Trump administration made, so whether the Medicare Coverage of Innovative Technology pathway will ever take effect is uncertain. But many providers and payers — and presumably most device makers — are keeping a close watch on the fate of the pathway.